FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2887706663> ?p ?o ?g. }

• W2887706663 endingPage "4542" @default.
• W2887706663 startingPage "4542" @default.
• W2887706663 abstract "Abstract Introduction: Liquid biopsy-based detection and monitoring of tumor-specific somatic mutations in cell-free DNA has great potential to improve patient care by detecting cancer early, assisting adjuvant therapy decision-making, monitoring residual disease, determining treatment effects, assessing relapse and the consequent need for follow-up intervention. We have developed a novel highly sensitive and specific approach for the detection and quantification of circulating tumor DNA (ctDNA) by tracking personalized cancer signatures in plasma. We recently described our ability to detect ctDNA presence longitudinally in patients with non-small cell lung cancer (NSCLC) and have validated this personalized approach for detection of tumor DNA in plasma, and made it available for research use only (RUO). Summary of Experimental Procedures: This study describes results of the Signatera RUO assay's analytical validation test titrations of cancer cell lines and their matched normal counterparts. Multiplex-PCR (mPCR) assay pools specific to the tumor mutational signatures were derived from whole-exome data analysis of the tumor cell line and its corresponding matched normal cell line. Tumor DNA spike-in mixtures were amplified using the mPCR assays and then barcoded and sequenced at ultra-high depth on the Illumina HiSeq instrument (average &gt; 100,000 reads per target). This study also demonstrates the ability to detect ctDNA using Signatera RUO assay's personalized somatic mutations in patients with epithelial and non-epithelial ovarian cancer. Results/Data Summary: The Signatera RUO analytical validation results demonstrate a variant-level sensitivity of ~60% at spiked-in tumor DNA concentrations of 0.03% along with an assay specificity of 99.9% in wild-type DNA. By targeting 16 somatic mutations present in the tumor, an estimated LOD of 0.01% tumor DNA in a patient's plasma is achieved. The Signatera RUO assay also demonstrates the ability to detect ctDNA in plasma down to less than 0.1% VAF at baseline (prior to treatment) in epithelial and non-epithelial ovarian cancer. Conclusion: The Signatera RUO assay provides a unique method to noninvasively detect ctDNA by assaying for personalized cancer signatures in plasma by ultra-high-depth sequencing of custom-made multiplex PCR assays, with high sensitivity and high specificity. Our study demonstrates the potential of this technology to improve the current standard of care by enabling early recurrence detection and the monitoring of treatment effectiveness across several tumor types. Citation Format: Himanshu Sethi, Raheleh Salari, Samantha Navarro, Prashanthi Natarajan, Ramya Srinivasan, Scott Dashner, Tony Tin, Mustafa Balcioglu, Ryan Swenerton, Bernhard Zimmermann. Analytical validation of the SignateraTM RUO assay, a highly sensitive patient-specific multiplex PCR NGS-based noninvasive cancer recurrence detection and therapy monitoring assay [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl):Abstract nr 4542." @default.
• W2887706663 created "2018-08-22" @default.
• W2887706663 creator A5018310163 @default.
• W2887706663 creator A5025067609 @default.
• W2887706663 creator A5028662238 @default.
• W2887706663 creator A5048740673 @default.
• W2887706663 creator A5057699016 @default.
• W2887706663 creator A5059305173 @default.
• W2887706663 creator A5065344327 @default.
• W2887706663 creator A5067488577 @default.
• W2887706663 creator A5067497340 @default.
• W2887706663 creator A5067930944 @default.
• W2887706663 date "2018-07-01" @default.
• W2887706663 modified "2023-10-03" @default.
• W2887706663 title "Abstract 4542: Analytical validation of the SignateraTM RUO assay, a highly sensitive patient-specific multiplex PCR NGS-based noninvasive cancer recurrence detection and therapy monitoring assay" @default.
• W2887706663 doi "https://doi.org/10.1158/1538-7445.am2018-4542" @default.
• W2887706663 hasPublicationYear "2018" @default.
• W2887706663 type Work @default.
• W2887706663 sameAs 2887706663 @default.
• W2887706663 citedByCount "8" @default.
• W2887706663 countsByYear W28877066632021 @default.
• W2887706663 countsByYear W28877066632022 @default.
• W2887706663 countsByYear W28877066632023 @default.
• W2887706663 crossrefType "journal-article" @default.
• W2887706663 hasAuthorship W2887706663A5018310163 @default.
• W2887706663 hasAuthorship W2887706663A5025067609 @default.
• W2887706663 hasAuthorship W2887706663A5028662238 @default.
• W2887706663 hasAuthorship W2887706663A5048740673 @default.
• W2887706663 hasAuthorship W2887706663A5057699016 @default.
• W2887706663 hasAuthorship W2887706663A5059305173 @default.
• W2887706663 hasAuthorship W2887706663A5065344327 @default.
• W2887706663 hasAuthorship W2887706663A5067488577 @default.
• W2887706663 hasAuthorship W2887706663A5067497340 @default.
• W2887706663 hasAuthorship W2887706663A5067930944 @default.
• W2887706663 hasConcept C104317684 @default.
• W2887706663 hasConcept C121608353 @default.
• W2887706663 hasConcept C126322002 @default.
• W2887706663 hasConcept C134305767 @default.
• W2887706663 hasConcept C142724271 @default.
• W2887706663 hasConcept C152110520 @default.
• W2887706663 hasConcept C153911025 @default.
• W2887706663 hasConcept C172680121 @default.
• W2887706663 hasConcept C204787440 @default.
• W2887706663 hasConcept C2778258057 @default.
• W2887706663 hasConcept C2778461978 @default.
• W2887706663 hasConcept C2779234561 @default.
• W2887706663 hasConcept C2779529041 @default.
• W2887706663 hasConcept C2779823535 @default.
• W2887706663 hasConcept C2780367336 @default.
• W2887706663 hasConcept C2781188995 @default.
• W2887706663 hasConcept C49105822 @default.
• W2887706663 hasConcept C502942594 @default.
• W2887706663 hasConcept C54355233 @default.
• W2887706663 hasConcept C552990157 @default.
• W2887706663 hasConcept C60644358 @default.
• W2887706663 hasConcept C70721500 @default.
• W2887706663 hasConcept C71924100 @default.
• W2887706663 hasConcept C86803240 @default.
• W2887706663 hasConcept C90583042 @default.
• W2887706663 hasConceptScore W2887706663C104317684 @default.
• W2887706663 hasConceptScore W2887706663C121608353 @default.
• W2887706663 hasConceptScore W2887706663C126322002 @default.
• W2887706663 hasConceptScore W2887706663C134305767 @default.
• W2887706663 hasConceptScore W2887706663C142724271 @default.
• W2887706663 hasConceptScore W2887706663C152110520 @default.
• W2887706663 hasConceptScore W2887706663C153911025 @default.
• W2887706663 hasConceptScore W2887706663C172680121 @default.
• W2887706663 hasConceptScore W2887706663C204787440 @default.
• W2887706663 hasConceptScore W2887706663C2778258057 @default.
• W2887706663 hasConceptScore W2887706663C2778461978 @default.
• W2887706663 hasConceptScore W2887706663C2779234561 @default.
• W2887706663 hasConceptScore W2887706663C2779529041 @default.
• W2887706663 hasConceptScore W2887706663C2779823535 @default.
• W2887706663 hasConceptScore W2887706663C2780367336 @default.
• W2887706663 hasConceptScore W2887706663C2781188995 @default.
• W2887706663 hasConceptScore W2887706663C49105822 @default.
• W2887706663 hasConceptScore W2887706663C502942594 @default.
• W2887706663 hasConceptScore W2887706663C54355233 @default.
• W2887706663 hasConceptScore W2887706663C552990157 @default.
• W2887706663 hasConceptScore W2887706663C60644358 @default.
• W2887706663 hasConceptScore W2887706663C70721500 @default.
• W2887706663 hasConceptScore W2887706663C71924100 @default.
• W2887706663 hasConceptScore W2887706663C86803240 @default.
• W2887706663 hasConceptScore W2887706663C90583042 @default.
• W2887706663 hasIssue "13_Supplement" @default.
• W2887706663 hasLocation W28877066631 @default.
• W2887706663 hasOpenAccess W2887706663 @default.
• W2887706663 hasPrimaryLocation W28877066631 @default.
• W2887706663 hasRelatedWork W1980837114 @default.
• W2887706663 hasRelatedWork W2623345365 @default.
• W2887706663 hasRelatedWork W2887706663 @default.
• W2887706663 hasRelatedWork W2914960150 @default.
• W2887706663 hasRelatedWork W3029147146 @default.
• W2887706663 hasRelatedWork W3083560286 @default.
• W2887706663 hasRelatedWork W4200359452 @default.
• W2887706663 hasRelatedWork W4243868329 @default.
• W2887706663 hasRelatedWork W4361009198 @default.
• W2887706663 hasRelatedWork W4381714968 @default.

• next